Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT, Nimenrix™): A Review of Its Immunogenicity, Safety, Co-administration, and Antibody Persistence

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2016 Feb 23

PMID 26900984

Citations 7

Authors

Aia Assaf-Casals

Ghassan Dbaibo

Affiliations

Soon will be listed here.

Abstract

Introduction: Meningococcal disease is a major cause of morbidity and mortality worldwide with reported epidemics and outbreaks in different parts of the world. Despite the availability of antimicrobial therapy, challenges remain in early recognition and prevention of disease. Several vaccines have been developed to date aiming at preventing disease spread.

Discussion: MenACWY-TT (Nimenrix™) has been extensively studied for use in different age groups. Phase II and III randomized trials have demonstrated its immunogenicity when administered in children aged 1 year and older, adolescents and adults. It has an acceptable safety profile with minor adverse events comparable to other vaccines. Follow up studies have shown persistence of protective antibodies up to three years. MenACWY-TT was safely and effectively co-administered with different recommended vaccines.

Conclusion: MenACWY-TT is a safe and immunogenic vaccine that can be used to protect against these four serogroups in individuals older than 1 year of age.

Citing Articles

Travel vaccines throughout history.

Pavli A, Maltezou H Travel Med Infect Dis. 2022; 46:102278.

PMID: 35167951 PMC: 8837496. DOI: 10.1016/j.tmaid.2022.102278.

Development and Immunogenicity of a Brazilian Glycoconjugate vaccine against Meningococcal W in a Pilot Scale.

de Souza I, da Silva M, Bastos R, Pereira D, Figueira E, Jessouroun E Glycoconj J. 2021; 38(5):539-549.

PMID: 34515909 DOI: 10.1007/s10719-021-10016-w.

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.

Piazza F, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A Hum Vaccin Immunother. 2021; 18(1):1-10.

PMID: 34085900 PMC: 8920225. DOI: 10.1080/21645515.2021.1902701.

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study.

Dhingra M, Namazova-Baranova L, Arredondo-Garcia J, Kim K, Limkittikul K, Jantarabenjakul W Epidemiol Infect. 2021; 149:e90.

PMID: 33814028 PMC: 8080229. DOI: 10.1017/S0950268821000698.

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.

Dretler A, Rouphael N, Stephens D Hum Vaccin Immunother. 2018; 14(5):1146-1160.

PMID: 29543582 PMC: 6067816. DOI: 10.1080/21645515.2018.1451810.

References

Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller J . Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. Drugs Aging. 2013; 30(5):309-19. PMC: 3634976. DOI: 10.1007/s40266-013-0065-0. View

Xie O, Pollard A, Mueller J, Norheim G . Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine. 2013; 31(27):2852-61. DOI: 10.1016/j.vaccine.2013.04.036. View

Diallo A, Sow S, Idoko O, Hirve S, Findlow H, Preziosi M . Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years. Clin Infect Dis. 2015; 61 Suppl 5:S521-30. PMC: 4639491. DOI: 10.1093/cid/civ518. View

Van Damme P, van der Wielen M . Combining hepatitis A and B vaccination in children and adolescents. Vaccine. 2001; 19(17-19):2407-12. DOI: 10.1016/s0264-410x(00)00464-3. View

Leonardi M, Latiolais T, Sarpong K, Simon M, Twiggs J, Lei P . Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy. Vaccine. 2014; 33(7):933-41. DOI: 10.1016/j.vaccine.2014.08.027. View

Knuf M, Baine Y, Bianco V, Boutriau D, Miller J . Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccin Immunother. 2012; 8(7):866-72. PMC: 3495722. DOI: 10.4161/hv.20229. View

Sambo L, Chan M, Davis S, Lake A, Berkley S, Poonawalla C . A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan Africa. Clin Infect Dis. 2015; 61 Suppl 5:S387-8. PMC: 4639480. DOI: 10.1093/cid/civ490. View

Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J . Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine. 2011; 29(25):4274-84. DOI: 10.1016/j.vaccine.2011.03.043. View

Tapia M, Findlow H, Idoko O, Preziosi M, Kulkarni P, Enwere G . Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age. Clin Infect Dis. 2015; 61 Suppl 5:S514-20. PMC: 4639509. DOI: 10.1093/cid/civ672. View

10.

Caugant D, Maiden M . Meningococcal carriage and disease--population biology and evolution. Vaccine. 2009; 27 Suppl 2:B64-70. PMC: 2719693. DOI: 10.1016/j.vaccine.2009.04.061. View

11.

Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J . Meningococcal disease. N Engl J Med. 2001; 344(18):1378-88. DOI: 10.1056/NEJM200105033441807. View

12.

Ghanem S, Hassan S, Saad R, Dbaibo G . Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review. Expert Opin Biol Ther. 2013; 13(8):1197-205. DOI: 10.1517/14712598.2013.812629. View

13.

Muthukkumar S, Stein K . Immunization with meningococcal polysaccharide-tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice. Vaccine. 2004; 22(9-10):1290-9. DOI: 10.1016/j.vaccine.2003.08.047. View

14.

Roderick M, Finn A . Advances towards the prevention of meningococcal B disease: a multidimensional story. J Infect. 2013; 68 Suppl 1:S76-82. DOI: 10.1016/j.jinf.2013.09.026. View

15.

Andrews N, Borrow R, Miller E . Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003; 10(5):780-6. PMC: 193909. DOI: 10.1128/cdli.10.5.780-786.2003. View

16.

Aguado M, Jodar L, Granoff D, Rabinovich R, Ceccarini C, Perkin G . From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project. Clin Infect Dis. 2015; 61 Suppl 5:S391-5. PMC: 4639495. DOI: 10.1093/cid/civ593. View

17.

Safadi M, Cintra O . Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res. 2010; 32(3):263-71. DOI: 10.1179/016164110X12644252260754. View

18.

Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P . A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2009; 28(3):744-53. DOI: 10.1016/j.vaccine.2009.10.064. View

19.

Lingappa J, Al-Rabeah A, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T . Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003; 9(6):665-71. PMC: 3000138. DOI: 10.3201/eid0906.020565. View

20.

Frasch C, Borrow R, Donnelly J . Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009; 27 Suppl 2:B112-6. DOI: 10.1016/j.vaccine.2009.04.065. View